Leaders in BioBanking Congress 2015 - バイオバンクリーダー学会、2015年 -
2015年7月14 - 16日
カナダ、オンタリオ州、トロント、インター コンチネンタル トロント センター

現在生体試料の収集は、さまざまな研究グループが行っており、その目的も基礎研究から臨床試験まで多岐にわたっています。質の高い生物学的研究を行うためには、しっかりと管理されたバイオバンクが必要不可欠です。また生体試料の適切な収集、処理、保存、追跡は、研究者が分子情報と臨床情報をより良い形で連携させることが可能になるという点で極めて重要な要素となります。この意味で、バイオバンクが科学とビジネスの両方に関わってくるのは当然といえるでしょう。

Cambridge Healthtech Institute (CHI) 主催の第7回International Leaders in Biobanking Congress: Maximizing Your Investment in Biospecimensは、バイオバンクが有するビジネスと科学両方の側面に光を当てる学会です。会期中は、生物医学や生物薬剤学の研究者、規制機関の幹部、バイオリポジトリの管理者や職員などが一堂に会し、現在の最先端の生物医学研究で生体試料を効果的に利用していくための最適な戦略を探求します。


プレカンファレンス | 1日目 | 2日目 | 3日目 | ポストカンファレンス | 講演者


7月13日 (月)

1:00 pm ショートコースの登録手続き


1:30-5:30 プレカンファレンスショートコース*

* 別途参加登録が必要です。


5:00 メインカンファレンスの登録手続き


研究施設視察ツアーとレセプション:University Health Network (UHN) の生体試料研究プログラム

(参加定員50名)

6:00-8:00

5:45 研究施設視察ツアーの送迎バス出発

* Intercontinental Toronto Centreと研究施設の間を往復する送迎サービスを無料でご利用いただけます。

6:00-8:00 視察ツアーとレセプション:UHNの生体試料研究プログラム

This tour at Canada's largest academic hospital system begins in surgical pathology with the banking of complex surgical specimens and data entry into our customized caTissueSuite research specimen management system. The tour continues to our laboratories for a demonstration of our state-of-the-art biospecimen information technology system, digital image analysis and laser capture microdissection.

8:00 送迎バスでホテルへ移動

8:15 プレカンファレンスセッション終了


プレカンファレンス | 1日目 | 2日目 | 3日目 | ポストカンファレンス | 講演者


7月14日 (火)

7:30 am メインカンファレンスの登録手続き、コーヒー


基調セッション:求められるコミュニティ全体としての取り組み

8:00 歓迎の挨拶と議長による開会の言葉

Michael RoehrlMichael H. A. Roehrl, M.D., Ph.D., Director, UHN Program in BioSpecimen Sciences, University Health Network and University of Toronto

8:15 病理学者が生体試料管理者として担う責務の複雑さ

Sylvia AsaSylvia L. Asa, M.D., Ph.D., Pathologist-in-Chief, Medical Director, Laboratory Medicine Program, University Health Network; Lakeridge Health & Women's College Hospital; Senior Scientist, Ontario Cancer Institute; Professor, Laboratory Medicine & Pathobiology, University of Toronto

Pathologists have responsibility for handling patient biospecimens; they implement rigorous quality assurance of processes that determine how specimens are collected, processed, examined, reported and either destroyed, biobanked or retained on file. Pathology is ideally positioned to develop and oversee biobanks and because of its capacity for data generation, generally provides the greatest amount of information for specimen annotation. Pathology also is subject to mandatory requirements for retention of clinical records, including tissue blocks and slides, for legal and accreditation purposes, emphasizing the importance of collecting and documenting biospecimens for research.

9:00 電子健康記録 (HER) に連動するバイオバンクを利用した発見と実現:eMERGEネットワークの経験

Rex ChisholmRex L. Chisholm, Ph.D., Vice Dean, Scientific Affairs and Graduate Education; Adam and Richard T. Lind Professor, Medical Genetics, Northwestern University Feinberg School of Medicine

Biobanks linked to electronic health records (EHR) provide a unique opportunity to study the association between genetic variation and phenotypes. The eMERGE network, funded by the National Human Genome Research Institute, has not only demonstrated the utility of this approach, but has also begun to develop methods for associating specific genomic variants with EHRs and providing clinical decision support to assist care providers in the use of this information.

9:45 休憩

10:15 将来の利用に向けた研究試料の調製:機能性品質管理評価のための革新的な手法とバイオバンクのベストプラクティス

Andrew BrooksAndrew Brooks, Ph.D., COO, RUCDR Infinite Biologics; Associate Professor, Genetics, Rutgers University

The presentation focuses on biomarker development and translational research optimization by taking into account how samples are collected, selection of the best technology for sample bioprocessing, global biobanking best practices and how information on each sample should be stored to enhance data sharing throughout the research process. Specific topics to be discussed include:

  • Sample bioprocessing and quality control methods that maximize the utility of collected biospecimens for current and future research
  • Understanding the power of evolving genomic technologies and how to develop a sample-centric roadmap for future research use
  • The role of centralized biobanking and global data integration in real-time data mining and optimization of biospecimen resources
  • How to build scientific and operational biomarker development synergies through collaborations to increase research productivity

11:00 バイオリポジトリネットワークのための総合的な標準作業手順書の作成−CTRNetの経験

Brent SchacterBrent Schacter, M.D., FRCPC, Principal Investigator, CTRNet; Professor, Department of Internal Medicine, Section of Hematology/Oncology, College of Medicine, University of Manitoba/CancerCare Manitoba

The Canadian Tissue Repository Network is a consortium of Canadian tumour biorepositories that aims to enhance biobanking capacity and quality through standardization. To minimize the issue of variable biobanking practices, CTRNet has developed and maintained a comprehensive set of standard operating procedures (SOPs). The key elements of the CTRNet SOP development process will be described. Once developed, reviewed and ratified by CTRNet, the SOPs have been published on our website for public access (with over 15,000 downloads in over 60 countries).

11:45 セッション終了

12:00 pm プレゼンテーションを聞きながらの昼食会 (スポンサーを募集しています) または各自で昼食


質の高いバイオバンクの維持

2:00 議長の発言

Andrew BrooksAndrew Brooks, Ph.D., COO, RUCDR Infinite Biologics; Associate Professor, Genetics, Rutgers University

2:05 コミュニティ病院システムにおける全国的な生体試料収集ネットワークの構築と実現

Jeffrey OttoJeffrey Otto, MBA, Ph.D., National Director, Center for Translational Research, Institute for Research and Innovation, Catholic Health Initiatives

Catholic Health Initiatives is the fifth-largest health system in the U.S., with 100+ hospitals spread nationally. Within this community hospital system, the Center for Translational Research (CTR) has built a first-of-its-kind hub-and-spoke biorepository program. Key attributes of this biorepository include: 1) high physical biospecimen quality, 2) EMR-linked patient data, and 3) full chain of custody. This presentation discusses how this program was built.

2:35 在庫管理:バイオリポジトリにおける再編、整理統合、品質保証、スペースコスト

Sherilyn SawyerSherilyn J. Sawyer, Ph.D., Director, BWH/Harvard Cohorts Biorepository, Channing Division of Network Medicine, Brigham and Women's Hospital

Space and organization within the available space are two high-level concerns of the biorepository. We have recently undertaken a multiyear project to reorganize inventory in order to recover lost space and utilize space more efficiently. A cost/benefit analysis of this project contributes to understanding the true costs of space for biorepositories.

3:05 スポンサー提供のプレゼンテーション

Speaker to be Announced

3:20 スポンサー提供のプレゼンテーション

3:35 展示会ホールでの休憩、ポスター発表の見学

4:00 インフォームドコンセントおよびバイオバンクの古い試料に関する再度の同意獲得に利用可能なWebベースソリューション

Daniel ThielDaniel B. Thiel, Public Health Researcher, Health Services Organization and Policy, University of Michigan School of Public Health

Highlighting the results of a pilot web-based informed consent portal for legacy donors to the Michigan BioTrust for Health, this presentation explores practical and ethical challenges raised by informed consent for legacy donors to biobanks. In the case of Michigan's BioTrust, the legacy samples are residual dried bloodspots derived from state-mandated newborn screening. I also consider this experiment in light of broader implications for biobanks comprising legacy samples.

4:30 組織バンク、バイオインフォマティクス、電子医療記録 (EMR) :個別化医療の前提条件

K. Stephen SuhK. Stephen Suh, Ph.D., Director, Genomics and Biomarkers Program, John Theurer Cancer Center, Hackensack University Medical Center

Personalized medicine promises patient-tailored treatments that enhance patient care and decrease overall treatment costs by focusing on genetics and "-omics" data obtained from patient biospecimens and records to guide therapy choices that generate good clinical outcomes. The approach relies on diagnostic and prognostic use of novel biomarkers discovered through combinations of tissue banking, bioinformatics and electronic medical records (EMRs).

5:00 パネルディスカッション:効果的な利用によるバイオバンクの価値確保

Biobanks are necessary and expensive research infrastructures. The ability to demonstrate effective utilization of biobanks is a quality measure that is essential for both financial and social sustainability. This panel discusses approaches for effective utilization of specimens from biobanks, both in the establishment of new biobanks and in the use of legacy collections.

Moderators:

Marianne-HendersonMarianne K. Henderson, MS, CPC, Chief, Division of Cancer Epidemiology & Genetics, Office of Division Operations and Analysis and the Center for Global Health, National Cancer Institute; Chair, Organizing Advisory Committee, ISBER



Marianna BledsoeMarianna J. Bledsoe, MA, Adjunct Assistant Professor, Department of Clinical Research and Leadership, George Washington University School of Medicine and Health Sciences; Co-Chair, Science Policy Committee, ISBER

Panelists:

Jeffrey OttoJeffrey Otto, MBA, Ph.D., National Director, Center for Translational Research, Institute for Research and Innovation, Catholic Health Initiatives

Sherilyn SawyerSherilyn J. Sawyer, Ph.D., Director, BWH/Harvard Cohorts Biorepository, Channing Division of Network Medicine, Brigham and Women's Hospital

K. Stephen SuhK. Stephen Suh, Ph.D., Director, Genomics and Biomarkers Program, John Theurer Cancer Center, Hackensack University Medical Center

Daniel ThielDaniel B. Thiel, Public Health Researcher, Health Services Organization and Policy, University of Michigan School of Public Health

Additional Panelists to be Announced

6:00 展示会ホールでの歓迎レセプション、ポスター発表の見学

7:00 1日目終了


プレカンファレンス | 1日目 | 2日目 | 3日目 | ポストカンファレンス | 講演者


7月15日 (水)

7:30 am プレゼンテーションを聞きながらの朝食 (スポンサーを募集しています) またはコーヒー

8:00 バイオバンキングブレインストーミング:朝食をとりながらのグループ討論

コーヒーを飲みながらのグループ討論です。このセッションは、参加者が意見を出し合いながら、問題の解決策を探るという形で進行することになっており、多様な背景を持つ出席者がそれぞれの考えや経験を披露しながら、焦点となるトピックをめぐる協力関係を将来に向けて発展させていくための足がかりを築くことができます。

品質システム−バイオバンクのあらゆる要素が依拠する骨格

Michael BreardMichael Breard, MS, MT(ASCP)SBB, CQA(ASQ), PMP(PMI), Vice President, Consulting Services and Sale, AABB

  • What is a quality system?
  • Why is quality important?
  • How do you achieve quality?
  • Is quality expensive?
  • What does it take to reach your quality goal?

Inventory Management and Data Annotation

Rajiv Dhir, M.D., MBA, Chief, Pathology, Shadyside Hospital, University of Pittsburgh Health Systems

  • What is inventory management and how do you currently address your needs?
  • What are the most common problems you have with inventory management?
  • What are the most common data annotation needs seen by you and how do you address them?
  • How do you provide data to your clients/investigators? Do you utilize honest brokers?

生体試料、バイオマーカー、臨床試験

9:00 議長の発言

Jeffrey OttoJeffrey Otto, MBA, Ph.D., National Director, Center for Translational Research, Institute for Research and Innovation, Catholic Health Initiatives

9:05 特別講演:臨床試験を通じて精密医療の戦略を転帰へと展開していくための取り組み

Lillian SiuLillian L. Siu, M.D., FRCPC, Professor, University of Toronto; Medical Oncologist, Princess Margaret Cancer Centre

Clinical trial frameworks focusing on interpatient heterogeneity include histology-based trials to evaluate therapeutic targeting of different molecular aberrations harbored by patients with a single tumor type ("umbrella trials"); as well as those that are histology-agnostic, aberrationspecific to encompass the assessment of similar molecular changes across different tumor types ("basket trials"). In this presentation, the benefits and challenges of genomics-based clinical trials are discussed, including a forecast into the next-generation precision medicine-based clinical research.


9:35 多中心型リンパ腫治療薬の臨床試験における相関研究のための生体試料調達

Koren MannKoren Mann, Ph.D., Assistant Professor, Oncology, Lady Davis Institute for Medical Research, McGill University

To develop novel agents in lymphoma, we must understand the molecular changes induced by these drugs, particularly in the context of clinical trials. We have developed a series of standard operating procedures (SOPs) to collect quality biospecimens for multiple downstream applications, including immunohistochemistry, exome sequencing, gene expression profiling, metabolomics and circulating tumor DNA. These SOPs were then validated in the context of the Q-CROC2 trial testing the efficacy of the histone deacetylase inhibitor, panobinostat, +/- rituximab in diffuse large B-cell lymphoma.

10:05 スポンサー提供のプレゼンテーション

10:35 展示会ホールでの休憩、ポスター発表の見学

11:15 ケーススタディ#1:生体試料の科学、臨床試験、精密医療:実務の事例

Michael RoehrlMichael H. A. Roehrl, M.D., Ph.D., Director, UHN Program in BioSpecimen Sciences, University Health Network and University of Toronto

Anthony JoshuaAnthony M. Joshua, MBBS, Ph.D., Staff Oncologist/Affiliate Scientist, Princess Margaret Cancer Centre

We discuss the use of human biospecimens for translational research, in particular molecularly driven clinical trials and our Rapid Autopsy Program. We discuss optimal collection, use and quality of samples, patient enrollment and consent, and integrated clinical and research data collection and annotation.

12:00 pm セッション終了

12:15 プレゼンテーションを聞きながらの昼食会 (スポンサーを募集しています) または各自で昼食


生体試料の品質を評価するための手段

2:00 議長の発言

Galen-HostetterGalen Hostetter, M.D., FCAP, Associate Director, Pathology Core, Van Andel Research Institute





2:05 研究段階から臨床段階へ: (事前) 解析変数とアッセイの開発

Veronique NeumeisterVeronique Neumeister, M.D., Laboratory Director, Specialized Translational Services Lab, Department of Pathology, Yale University School of Medicine

Companion diagnostic tests are critically dependent on tissue quality. However, tissue handling and processing are not always tightly controlled and pre-analytical variables can significantly alter tissue quality. This presentation focuses on the effects of (pre-)analytical variables in the diagnostic and research setting. Methodology and importance of quality control, optimization and standardization of tissue processing, biomarker validation and development of useful laboratory tests for the clinical setting will be discussed.

2:30 ヒトのバイオバンク業務の参考となる実験動物のモデル

Galen-HostetterGalen Hostetter, M.D., FCAP, Associate Director, Pathology Core, Van Andel Research Institute

Experimental animal models have been widely used to inform veterinary and human pathophysiology with associated improved control of pre-analytic variables to include single marker QC probes or next-generation genomic sequencing of disaggregated tissue samples. We demonstrate animal experiments to combine tissue morphology and expressed protein by IHC, qualitative/quantitative measures of nucleic acids by RIN and Q-ratios, respectively, to assess effect of pre-analytic variables and provide the basis for standardized methods in tissue sample collection and processing.

2:55 加圧凍結:凍結保存のための新たな手法

Nickolas GreerNickolas Greer, CSO, Rissali LLC

Chemical cryoprotectants are toxic to live cells, tissues and organs. Cryoprotectant toxicity increases with concentration. Both hydraulic pressure and cryoprotectants increase viscosity of aqueous solutions at the freezing point, inhibit ice crystal growth and induce vitrification of water. By applying pressure during freezing it may be possible to reduce concentration or eliminate cryoprotectants for preservation of viable biological materials, thereby solving the cryoprotectant toxicity problem.

3:20 血液銀行で使用される変性加工ソリューションで収集、保存された赤色細胞のマイクロ流体デバイスによる評価

Dana SpenceDana Spence, Ph.D., Associate Professor, Department of Chemistry, Michigan State University

The collection and storage solutions used to process erythrocytes for storage in transfusion medicine contain levels of glucose that are nearly 10-15x higher than that found in the circulation of a healthy human. Here, data is presented demonstrating that maintenance of normoglycemic levels during the blood storage process helps to maintain certain properties of the stored cells, even beyond five weeks in storage.

3:45 スポンサー提供のプレゼンテーション

4:15 展示会ホールでの休憩、ポスター発表の見学


4:50 特別講演:多施設共同研究での免疫モニタリングに対応する末梢血標本に影響を及ぼす解析前変数

Amit Bar-OrAmit Bar-Or, M.D., FRCPC, Professor, Neurology & Neurosurgery; Director, Experimental Therapeutics Program and Scientific Director, Clinical Research Unit, Montreal Neurological Institute, McGill University

While there has been rapid growth in multicenter biomarker-development and immune-monitoring initiatives, including a major investment in procuring biological samples for cell-based assays, relatively little has been done to formally assess the impact of pre-analytical variables on functional immune responses within such samples. This presentation considers the impact of shipping approach and ambient temperature on such readouts.



ケーススタディ:バイオバンクと利用者の協力

Biomedical researchers and drug developers require accessible, highquality biospecimens that allow them to extract reliable and useful data. Oncology experts, for instance, use patient-derived tumor collections to connect datasets, pinpoint and assess variants within cancer patients post-diagnosis and zero in on the data that matter when tailoring therapies. Early, strategic collaborations with the biobanks that house specimens can be mutually beneficial, maximizing the financial and technological investments of the operation managers who collect, store, annotate and distribute the biological samples ("biobankers") and supporting the research goals of the scientists who need those samples ("biousers") - all to fulfill the promise of personalized medicine.


5:15 ケーススタディ#2

6:00 セッション終了

6:00 ショートコースの登録手続き


6:15-9:30 ディナーショートコース*

* 別途参加登録が必要です。


プレカンファレンス | 1日目 | 2日目 | 3日目 | ポストカンファレンス | 講演者


7月16日 (木)

7:30 am プレゼンテーションを聞きながらの朝食 (スポンサーを募集しています) またはコーヒー


専門分野に特化したバイオバンク

8:00 議長の発言

Marianna BledsoeMarianna J. Bledsoe, MA, Adjunct Assistant Professor, Department of Clinical Research and Leadership, George Washington University School of Medicine and Health Sciences; Co-Chair, Science Policy Committee, ISBER

8:05 iPS細胞バイオバンクの将来像

Jonathan Y.H. LohJonathan Y.H. Loh, Ph.D., Assistant Professor, Department of Biological Sciences, National University of Singapore, A*STAR Institute of Molecular and Cell Biology

We have developed the technology for efficient derivation of transgene-free hiPSCs from human finger-prick blood. Finger-prick sample collection can be performed on a "do-it-yourself" basis by donors and sent to the hiPSC facility for reprogramming. We show that single-drop volumes of finger-prick samples are sufficient for performing cellular reprogramming, DNA sequencing, and blood serotyping in parallel. Our novel strategy has the potential to facilitate the development of large-scale hiPSC banking worldwide.

8:35 心臓移植の転帰改善を目的としたバイオバンク

Dawn BowlesDawn E. Bowles, Ph.D., Assistant Professor, Department of Surgery, Division of Surgical Sciences and Co-Director, Duke Human Heart Repository

A human cardiac transplant biorepository for research on improving cardiac transplantation outcomes has been established. Evidence indicates an association between the levels of cardiac injury biomarkers in the preservation/transportation fluid from the donor heart of transplant cases and the development of inadequate cardiac function post-implant in the recipient. Continued evaluation of the preservation fluid will lead to better understanding of preservation injury and optimization of preservation/transport solutions for cardiac transplant.

9:05 子どもと女性のための制度化された病院の計画立案と実施:倫理面と運用面の課題

Suzanne VercauterenSuzanne Vercauteren, M.D., Ph.D., FRCPC, Head, Division of Hematopathology, BC Children's Hospital and Clinical Assistant Professor, Pathology and Laboratory Medicine, University of British Columbia

The BCCH BioBank's goal is to ethically collect biospecimens and clinical data from pediatric and adult patients with a range of conditions and store them systematically for future research. Its founding principles include public engagement, long-term sustainability and high-quality specimens. Its planning and implementation was a complex process that involved detailed consideration of the ethical issues concerning the different types of potential participants and careful consideration of the operational structure of the biobank.

9:35 スポンサー提供のプレゼンテーション

10:05 展示会ホールでの休憩、ポスター発表の見学


10:45 University Health Network (UHN) の泌尿生殖器バイオバンク

Neil FleshnerNeil Fleshner, M.D., MPH, FRCSC, Chair, Urology, Department of Surgery, University of Toronto; Head, Urology, University Health Network; Director, GU BioBank, Princess Margaret Cancer Centre

The GU (genitourinary) BioBank is a predominantly bio-fluid-based program that follows consenting GU oncology participants over time, obtaining additional specimens and data at predefined intervals and upon any change in clinical state. This capacity for frequent and long-term follow-up has been made possible by integrating the BioBanking process with clinical care at UHN. The GU BioBank has garnered an incredible amount of interest in recent years. We share our experience in setting up and maintaining this patient-centered research program.

11:15 ケーススタディ#3 (スポンサーを募集しています)

12:00 pm セッション終了

12:15 プレゼンテーションを聞きながらの昼食会 (スポンサーを募集しています) または各自で昼食


専門性の高いバイオバンク (続き)

2:00 議長の発言

Marianne-HendersonMarianne K. Henderson, MS, CPC, Chief, Division of Cancer Epidemiology & Genetics, Office of Division Operations and Analysis and the Center for Global Health, National Cancer Institute; Chair, Organizing Advisory Committee, ISBER



2:05 カナダの国立臍帯血バンクの概要

Heidi ElmoazzenHeidi Elmoazzen, Ph.D., Director, National Public Cord Blood Bank

Canadian Blood Services is building a National Public Cord Blood Bank which consists of five collection sites in four cities: Ottawa, Brampton, Edmonton and Vancouver, as well as two manufacturing facilities in Ottawa and Edmonton. An overview of the sources and use of hematopoietic stem cells as well as an overview of cord blood processing, cryopreservation and storage will be provided.

2:35 トロント肺移植バイオバンクプロジェクトで収集されている試料

Sassan AzadSassan M. Azad, Project Manager, Clinical, Translational & Biobanking Research Office, Toronto Lung Transplant Program, Toronto General Hospital, University Health Network

The Toronto Lung Transplant Program, one of the world's largest, is supporting clinical research in end-stage lung disease and advancing lung transplantation. Two major areas that limit successful application of lung transplantation are ischemia reperfusion injury (IRI) and bronchiolitis obliterans (BO). Our work explores underlying mechanisms of both these injuries and the development of therapeutic strategies to prevent or reverse them. Our current research focus is on biomarker discovery and gene therapy in lung transplantation.

3:05 休憩、展示会とポスター発表を見学する最後のチャンスです


ITを利用した質の高いバイオバンクの維持

4:15 拡張可能な研究データリポジトリにおける臨床データおよびバイオリポジトリデータ収集の進展

Maureen E. Lane, Ph.D., Assistant Professor, Medicine; Director, Hem/Onc Translational Core Laboratory, The Leukemia Biorepository and Personalized Medicine Center, Weill Cornell Medical College

The Leukemia group at Weill Cornell Medical Center has been working with our information technology services (ITS) group to develop a Research Data Repository (RDR) that marries relevant clinical data with samples from our AML biorepository. This project is one of three pilot projects with a focus on supporting Precision Medicine and translational research at Weill Cornell.

4:40 トランスレーショナルリサーチと基礎研究のためのデータバンクとバイオリポジトリ

Annmarie NowakAnnmarie Nowak, Coordinator & Director, Data Bank and Biorepository, Biobanking Systems Integration Cancer Prevention and Population Science, Roswell Park Cancer Institute

The Data Bank and BioRepository (DBBR) at Roswell Park Cancer Institute is a comprehensive data and sample bank, with biospecimens, epidemiologic and clinical information for investigators conducting translational research related to cancer prevention, etiology, detection and treatment. We discuss our recruitment, procurement and processing procedures, the structure and function of LIMS and the integration of clinical, research and biospecimen data.

5:05 質の高いバイオバンクの実現とバイオバンクの質向上に向けた取り組み:CRIP ToolBoxとメタバイオバンクフレームワークp-BioSPRE

Christina SchröderChristina Schröder, Ph.D., Head, Metabiobanks CRIP, Fraunhofer Institute for Cell Therapy and Immunology

While biobank registries and catalogs will at best allow queries for specific biobank collections or cohorts, trans-institutional metabiobanks enable parameterized, stratified, though privacy-preserving queries in connected biobanks on a case-by-case and sample-by-sample basis. Building such metabiobanks for a decade, and drawing upon broad expertise in semantic data integration across sectors relevant for translational biomedical research, we have developed the metabiobank software suite "CRIP Toolbox". We showcase p-BioSPRE, the metabiobank setup for the EU FP 7-funded project p-medicine, as a multipurpose tool to internationally access and promote quality biobanks online.

5:30 学会閉幕


プレカンファレンス | 1日目 | 2日目 | 3日目 | ポストカンファレンス | 講演者


ポストカンファレンスイベント

7月17日 (金)


バイオバンクを利用した研究のためのインフォームドコンセントの内容と
手続きの要件*

8:30 am-5:00 pm



This course presents the elements of the informed consent document and the components of the process, specifically as they relate to biobanking studies.

Instructor: Elizabeth Ronk Nelson, MPH, Barnett International


Participants will receive 7 hours (0.7 CEUs) from Accreditation Council for Pharmacy Education for full participation. For further information please visit barnettinternational.com

* 別途参加登録が必要です。



プレカンファレンス | 1日目 | 2日目 | 3日目 | ポストカンファレンス | 講演者

* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。

Choose your language
Traditional Chinese
Simplified Chinese
Korean
English

Co-Hosted by
University Health Network logo

» メディアパートナー

Catalog

イベントカレンダー
メール配信サービス